PRIMARY CHEMOTHERAPY FOR CLINICAL STAGE-II NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - A FOLLOW-UP OF 50 PATIENTS

被引:69
作者
LOGOTHETIS, CJ
SWANSON, DA
DEXEUS, F
CHONG, C
OGDEN, S
AYALA, AG
VONESCHENBACH, AC
JOHNSON, DE
SAMUELS, ML
机构
[1] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT UROL,HOUSTON,TX 77030
[2] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT PATHOL,HOUSTON,TX 77030
关键词
D O I
10.1200/JCO.1987.5.6.906
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:906 / 911
页数:6
相关论文
共 12 条
[1]  
DEWYS WD, 1984, ADJUVANT THERAPY CAN, V4, P529
[2]  
JAVADPOUR N, 1979, J UROL, V135, P497
[3]  
LOGOTHETIS CJ, 1982, CANCER, V50, P1629, DOI 10.1002/1097-0142(19821015)50:8<1629::AID-CNCR2820500828>3.0.CO
[4]  
2-1
[5]   SURGERY IN THE MANAGEMENT OF STAGE-III GERMINAL CELL TUMORS - OBSERVATIONS ON THE MD-ANDERSON-HOSPITAL EXPERIENCE, 1971-1979 [J].
LOGOTHETIS, CJ ;
SAMUELS, ML .
CANCER TREATMENT REVIEWS, 1984, 11 (01) :27-37
[6]   IMPROVED SURVIVAL WITH CYCLIC CHEMOTHERAPY FOR NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS [J].
LOGOTHETIS, CJ ;
SAMUELS, ML ;
SELIG, D ;
SWANSON, D ;
JOHNSON, DE ;
VONESCHENBACH, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) :326-335
[7]   CYCLIC CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN PLUS VINBLASTINE AND BLEOMYCIN IN ADVANCED GERMINAL TUMORS - RESULTS WITH 100 PATIENTS [J].
LOGOTHETIS, CJ ;
SAMUELS, ML ;
SELIG, DE ;
OGDEN, S ;
DEXEUS, F ;
SWANSON, D ;
JOHNSON, D ;
VONESCHENBACH, A .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (02) :219-228
[8]   CLINICAL STAGE-II NONSEMINOTAMOUS GERM-CELL TESTICULAR-TUMORS - RESULTS OF MANAGEMENT BY PRIMARY CHEMOTHERAPY [J].
PECKHAM, MJ ;
HENDRY, WF .
BRITISH JOURNAL OF UROLOGY, 1985, 57 (06) :763-768
[9]   NO ADJUVANT CHEMOTHERAPY IN SELECTED PATIENTS WITH PATHOLOGIC STAGE-II NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS [J].
PIZZOCARO, G ;
MONFARDINI, S .
JOURNAL OF UROLOGY, 1984, 131 (04) :677-680
[10]   ADJUVANT THERAPY OF TESTIS CANCER - THE ROLE OF VINBLASTINE AND BLEOMYCIN [J].
SAMUELS, ML ;
JOHNSON, DE .
JOURNAL OF UROLOGY, 1980, 124 (03) :369-371